Polycystic Ovarian Syndrome - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H2 2018’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome

- The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects

- The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

EffRx Pharmaceuticals SA

Ogeda SA

Vicore Pharma AB

Addex Therapeutics Ltd

EffRx Pharmaceuticals SA

Ogeda SA

Vicore Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome – Overview

Polycystic Ovarian Syndrome – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome – Overview

Polycystic Ovarian Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Ovarian Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Ovarian Syndrome – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

EffRx Pharmaceuticals SA

Ogeda SA

Vicore Pharma AB

Polycystic Ovarian Syndrome – Drug Profiles

C-21 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metformin hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Ovarian Syndrome – Dormant Projects

Polycystic Ovarian Syndrome – Discontinued Products

Polycystic Ovarian Syndrome – Product Development Milestones

Featured News & Press Releases

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients

Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364

Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations

Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Polycystic Ovarian Syndrome – Pipeline by Addex Therapeutics Ltd, H2 2018

Polycystic Ovarian Syndrome – Pipeline by EffRx Pharmaceuticals SA, H2 2018

Polycystic Ovarian Syndrome – Pipeline by Ogeda SA, H2 2018

Polycystic Ovarian Syndrome – Pipeline by Vicore Pharma AB, H2 2018

Polycystic Ovarian Syndrome – Dormant Projects, H2 2018

Polycystic Ovarian Syndrome – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports